These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7822705)

  • 21. MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen.
    Brünner N; Boysen B; Jirus S; Skaar TC; Holst-Hansen C; Lippman J; Frandsen T; Spang-Thomsen M; Fuqua SA; Clarke R
    Cancer Res; 1997 Aug; 57(16):3486-93. PubMed ID: 9270017
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of transforming growth factor-beta responsiveness in the tamoxifen growth-inhibited human breast cancer cell line CAMA-1.
    Ji H; Stout LE; Zhang Q; Zhang R; Leung HT; Leung BS
    J Cell Biochem; 1994 Mar; 54(3):332-42. PubMed ID: 8200913
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transforming growth factor beta 1 is implicated in the failure of tamoxifen therapy in human breast cancer.
    Thompson AM; Kerr DJ; Steel CM
    Br J Cancer; 1991 Apr; 63(4):609-14. PubMed ID: 2021547
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of a receptor-negative, hormone-nonresponsive clone derived from a T47D human breast cancer cell line kept under estrogen-free conditions.
    Murphy CS; Pink JJ; Jordan VC
    Cancer Res; 1990 Nov; 50(22):7285-92. PubMed ID: 2224859
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Steroid-free medium discloses oestrogenic effects of the bisphosphonate clodronate on breast cancer cells.
    Journe F; Chaboteaux C; Dumon JC; Leclercq G; Laurent G; Body JJ
    Br J Cancer; 2004 Nov; 91(9):1703-10. PubMed ID: 15477866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial.
    Rasmussen BB; Regan MM; Lykkesfeldt AE; Dell'Orto P; Del Curto B; Henriksen KL; Mastropasqua MG; Price KN; Méry E; Lacroix-Triki M; Braye S; Altermatt HJ; Gelber RD; Castiglione-Gertsch M; Goldhirsch A; Gusterson BA; Thürlimann B; Coates AS; Viale G;
    Lancet Oncol; 2008 Jan; 9(1):23-8. PubMed ID: 18083065
    [TBL] [Abstract][Full Text] [Related]  

  • 27. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
    Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
    Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of colon and breast carcinoma cell growth by interleukin-4.
    Toi M; Bicknell R; Harris AL
    Cancer Res; 1992 Jan; 52(2):275-9. PubMed ID: 1728401
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibitory effect of hydroxyflutamide plus tamoxifen on oestradiol-induced growth of MCF-7 breast cancer cells.
    Di Monaco M; Brignardello E; Leonardi L; Gatto V; Boccuzzi G
    J Cancer Res Clin Oncol; 1995; 121(12):710-4. PubMed ID: 7499441
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The nature of tamoxifen action in the control of female breast cancer.
    Kodama M; Kodama T
    In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence.
    Mc Ilroy M; Fleming FJ; Buggy Y; Hill AD; Young LS
    Endocr Relat Cancer; 2006 Dec; 13(4):1135-45. PubMed ID: 17158759
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Induction of antiproliferation and apoptosis in estrogen receptor negative MDA-231 human breast cancer cells by mifepristone and 4-hydroxytamoxifen combination therapy: a role for TGFbeta1.
    Liang Y; Hou M; Kallab AM; Barrett JT; El Etreby F; Schoenlein PV
    Int J Oncol; 2003 Aug; 23(2):369-80. PubMed ID: 12851686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Acquisition of epithelial-mesenchymal transition phenotype in the tamoxifen-resistant breast cancer cell: a new role for G protein-coupled estrogen receptor in mediating tamoxifen resistance through cancer-associated fibroblast-derived fibronectin and β1-integrin signaling pathway in tumor cells.
    Yuan J; Liu M; Yang L; Tu G; Zhu Q; Chen M; Cheng H; Luo H; Fu W; Li Z; Yang G
    Breast Cancer Res; 2015 May; 17(1):69. PubMed ID: 25990368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-competitive steroid inhibition of oestrogen receptor functions.
    Puddefoot JR; Barker S; Glover HR; Malouitre SD; Vinson GP
    Int J Cancer; 2002 Sep; 101(1):17-22. PubMed ID: 12209583
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cellular heterogeneity and mutant oestrogen receptors in hormone resistant breast cancer.
    Horwitz KB
    Cancer Surv; 1992; 14():41-54. PubMed ID: 1423329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple forms of TGF-beta 1 in breast tissues: a biologically active form of the small latent complex of TGF-beta 1.
    Baillie R; Coombes RC; Smith J
    Eur J Cancer; 1996 Aug; 32A(9):1566-73. PubMed ID: 8911119
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of tamoxifen in the prevention and treatment of benign and malignant breast lesions: a chemopreventive.
    Leis HP
    Int Surg; 1993; 78(2):176-82. PubMed ID: 8354620
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tamoxifen-resistant fibroblast growth factor-transfected MCF-7 cells are cross-resistant in vivo to the antiestrogen ICI 182,780 and two aromatase inhibitors.
    McLeskey SW; Zhang L; El-Ashry D; Trock BJ; Lopez CA; Kharbanda S; Tobias CA; Lorant LA; Hannum RS; Dickson RB; Kern FG
    Clin Cancer Res; 1998 Mar; 4(3):697-711. PubMed ID: 9533540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Aurora kinase B is important for antiestrogen resistant cell growth and a potential biomarker for tamoxifen resistant breast cancer.
    Larsen SL; Yde CW; Laenkholm AV; Rasmussen BB; Duun-Henriksen AK; Bak M; Lykkesfeldt AE; Kirkegaard T
    BMC Cancer; 2015 Apr; 15():239. PubMed ID: 25885472
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of transforming growth factor beta 1 in human breast cancer in vivo following tamoxifen treatment.
    Butta A; MacLennan K; Flanders KC; Sacks NP; Smith I; McKinna A; Dowsett M; Wakefield LM; Sporn MB; Baum M
    Cancer Res; 1992 Aug; 52(15):4261-4. PubMed ID: 1322240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.